Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Purchases $23,940.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,000 shares of the stock in a transaction on Thursday, January 2nd. The shares were acquired at an average price of $11.97 per share, with a total value of $23,940.00. Following the transaction, the chief executive officer now directly owns 5,543,702 shares of the company’s stock, valued at $66,358,112.94. The trade was a 0.04 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Monday, December 30th, Snehal Patel bought 3,200 shares of Greenwich LifeSciences stock. The shares were acquired at an average price of $11.12 per share, for a total transaction of $35,584.00.

Greenwich LifeSciences Price Performance

Shares of NASDAQ GLSI opened at $12.88 on Monday. The stock has a market capitalization of $169.37 million, a P/E ratio of -16.10 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 1-year low of $8.00 and a 1-year high of $21.44. The business’s 50 day moving average is $13.20 and its two-hundred day moving average is $14.17.

Institutional Trading of Greenwich LifeSciences

Several hedge funds and other institutional investors have recently bought and sold shares of GLSI. Rhumbline Advisers purchased a new stake in shares of Greenwich LifeSciences in the second quarter valued at $117,000. Barclays PLC raised its position in Greenwich LifeSciences by 323.3% in the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock worth $123,000 after purchasing an additional 6,538 shares during the period. Garden State Investment Advisory Services LLC bought a new stake in Greenwich LifeSciences in the third quarter worth about $253,000. Bank of New York Mellon Corp bought a new stake in Greenwich LifeSciences in the second quarter worth about $264,000. Finally, State Street Corp boosted its position in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after buying an additional 3,005 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.